Evidence map›Paper›PMID 34199946›Full record

ArticleCancers2021

Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy.

Gayathri R Devi, Pascal Finetti, Michael A Morse, Seayoung Lee, Alexandre de Nonneville, Steven Van Laere, Jesse Troy, Joseph Geradts, Shannon McCall, Francois Bertucci

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Subtype-Independent Activation of NF-κB Signaling in Breast Cancer.International journal of molecular sciences · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Durian and Sapodilla Extracts Enhance Chemotherapy Sensitivity and Promote Apoptosis in Triple Negative Breast Cancer Model in Vitro: Systematic Review.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. A New Flavanone fromMolecules (Basel, Switzerland) · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Gayathri R DeviDivision of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Pascal FinettiLaboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 13009 Marseille, France.ORCID 0000-0002-2674-3123
Michael A MorseDepartment of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Seayoung LeeDivision of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Alexandre de NonnevilleLaboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 13009 Marseille, France.ORCID 0000-0001-6710-8284
Steven Van LaereGZA Hospitals Sint-Augustinus, 2018 Antwerp, Belgium.
Jesse TroyDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA.
Joseph GeradtsDepartment of Pathology and Laboratory Medicine, East Carolina University Brody School of Medicine, Greenville, NC 27858, USA.
Shannon McCallDepartment of Pathology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-3957-061X
Francois BertucciLaboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 13009 Marseille, France.
Duke Medical Center · USCentre National de la Recherche Scientifique · FRDuke University · USEast Carolina University · USGZA Ziekenhuizen Campus Sint-Augustinus · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

XIAP, the most potent inhibitor of cell death pathways, is linked to chemotherapy resistance and tumor aggressiveness. Currently, multiple XIAP-targeting agents are in clinical trials. However, the characterization of XIAP expression in relation to clinicopathological variables in large clinical series of breast cancer is lacking. We retrospectively analyzed non-metastatic, non-inflammatory, primary, invasive breast cancer samples for

Indexed as

anthracyclineapoptosiscell deathHER2luminal BmetastasispCRproteomicstaxanesTNXIAP

Identifiers

PMID34199946
PMCPMC8200223
OpenAlexW3169454487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.